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MGMT-TRANSDUCED gd T CELLS FUNCTION IN THE PRESENCE OF
TEMOZOLAMIDE AND SHOW ENHANCED CYTOTOXICITY AGAINST
TEMOZOLOMIDE-RESISTANT HIGH GRADE GLIOMA CELL LINES:
POTENTIAL STRATEGIES FOR COMBINATION OF CHEMOTHERAPY AND
IMMUNOTHERAPY
Lamb, L.S.1, Bowersock, J.1, Dasgupta, A.2, Gillespie, G.Y.1,
Spencer, H.T.2 1University of Alabama at Birmingham School of Medi-
cine, Birmingham, AL; 2Emory University School of Medicine, Atlanta,
GA
Treatment strategies for high-grade primary brain tumors such as
glioblastomamultiforme (GBM) have failed to significantly and con-
sistently extend survival. Recently, several studies have suggested that
chemotherapy-induced tumor stress may increase tumor vulnerabil-
ity to the immune reaponse. We have previously shown that ex-
panded/activated gd T cells from healthy donors recognize
NKG2D ligands expressed on malignant glioma and are cytotoxic
to glioma cell lines, primaryGBMexplants, and human glioma intra-
cranial cell line xenografts placed in immunodeficient mice. In this
report, we show standard therapies forGBMbased on temozolomide
(TMZ) increase the expression of stress-associated NKG2D ligands
on TMZ-resistant glioma cells, potentially rendering them vulnera-
ble to attack by gdT cells. As TMZ is also highly toxic to gdT cells,
we genetically modified gdT cells in culture using a lentiviral vector
encoding P140KMGMT, resulting in resistance to TMZ at concen-
trations up to 400mM.Geneticmodification ofgdTcells did not alter
their phenotype or their ability to kill targets, as both non-modified
and gene-modified gdT cells were highly cytotoxic to U87 cells and
TMZ-resistant clones of SNB-19 (SNB-19TMZ-R) and U373
(U373TMZ-R) glioma cell lines in the presence of up to 400 mM
TMZ. Importantly, gene modified gd T cells showed greater cyto-
toxicity to both U373TMZ-R and SNB-19TMZ-R cultures in the pres-
ence of TMZ, suggesting that TMZ exposed more targets to gd T
cell lysis. These findings demonstrate that TMZ resistant gd T cells
can be generated without impairing cellular functions, and the genet-
ically modified cells efficiently kill TMZ-resistant human glioma cell
lines in the presence of high concentrations of TMZ. These results
provide a mechanistic basis for combining and timing chemotherapy
and drug resistant cellular immunotherapy to treat GBM.
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PHASE I/II STUDY OF INTRAVENOUS PLERIXAFOR ADDED TO A MOBILI-
ZATION REGIMEN OF G-CSF IN LYMPHOMA PATIENTS UNDERGOING
AUTOLOGOUS STEM CELL COLLECTION
Cashen, A.1, Rettig, M.1, Gao, F.2, Reineck, T.1, Abboud, C.1, Stockerl-
Goldstein, K.1, Vij, R.1, Uy,G.1,Westervelt, P.1, DiPersio, J.1 1Washington
University School of Medicine, St. Louis, MO; 2Washington University
School of Medicine, St. Louis, MO
Background: In Phase II and III trials, plerixafor has been combined
with G-CSF and administered as a subcutaneous injection of 0.24
mg/kg, given 9-11 hours before pheresis. Intravenous (IV) adminis-
tration of plerixafor may result in a faster rise and higher peak in the
peripheral CD34+ cell count, allowing administration of plerixafor
the same day as pheresis and improving stem cell collection.
Methods:The primary objectives of this Phase I/II studywere to de-
termine the MTD of IV plerixafor, up to 0.40 mg/kg combined with
G-CSF, and the efficacy of IV plerixafor + G-CSF to mobilize$ 2 x
106 CD34+ cells/kg from pts. with lymphoma. Pts. started mobiliza-
tion with G-CSF (10 ug/kg SC daily) on days -4 thru -1 and on each
day of pheresis (up to 4 pheresis days). IV plerixafor was given over
30 min. 4 hrs. before each pheresis, beginning day 0.
Results: 46 pts. (median age, 53; 31 NHL/15HL) have been treated
to date. In Phase I, 25 pts. were treated with IV plerixafor at escalat-
ing doses (10 pts. at 0.16 mg/kg, 3 at 0.24 mg/kg, 6 at 0.32 mg/kg,
and 6 at 0.40 mg/kg). One dose-limiting toxicity (grade 2 chestpain) was observed at 0.32 mg/kg. In Phase II, an additional 21
pts. have been treated at 0.40 mg/kg. No grade 3/4 toxicities attrib-
uted to plerixafor occurred in any pt. treated at 0.40 mg/kg. Overall,
44 of 46 pts. (96%, 80%CI 89-99%)met the goal collection of$ 2.0
x 106 CD34+ cells/kg, and 37 of 46 pts. (80%, 80% CI 71-88%) col-
lected$ 5.0 x 106 CD34+ cells/kg, in a median 2 days of pheresis. 20
of 27 pts. (74%, 80% CI 60-85%) treated with 0.40 mg/kg collected
$ 2.0 x 106 CD34+ cells/kg in 1 day of pheresis. In transplanted pts.,
there has been no delay in engraftment. Analysis of CD34+ hemato-
poietic stem and progenitor cells (HSPCs) revealed that G-CSFmo-
bilized grafts were enriched with CD45RA-CD123+/- primitive
HSPCs while plerixafor preferentially mobilized CD34dimC-
D45RA+CD123hi plasmacytoid dendritic cell precursors and
CD34+CD45RA-CD123hi cells. Flow cytometric analyses showed
that the CD34+ subsets preferentially mobilized by plerixafor ex-
pressed high levels of cell surface CXCR4.
Conclusions: Plerixafor IV, at doses up to 0.40 mg/kg, is well-toler-
ated and effective when added toG-CSF for themobilization of stem
cells from pts. with lymphoma, with mobilization kinetics and stem
cell collections that compare favorably with sc dosing. In addition,
our data suggest that G-CSF and plerixafor mobilize distinct subsets
of human CD34+ HSPCs.
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COMPLEX KARYOTYPE (CK) IS ASSOCIATEDWITH INCREASED CUMULA-
TIVE INCIDENCE OF RELAPSE (CIR) FOLLOWING AUTOLOGOUS STEM
CELL TRANSPLANTATION (ASCT) FOR MANTLE CELL LYMPHOMA
(MCL) IN FIRST REMISSION
Cohen, J.B.1, Ruppert, A.S.1, Kaplan, L.D.2, Baiocchi, R.1, Porcu, P.1,
Flynn, J.1, Penza, S.1, Jones, J.A.1, Blum, K.A.1, Devine, S.M.1,
Andritsos, L.A.1 1The Ohio State University- James Cancer Center, Co-
lumbus, OH; 2University of California, San Francisco, San Francisco, CA
Introduction: Complex cytogenetics predict patient outcomes and
response to therapy in many hematologic malignancies, but there
are few data regarding their significance in patients undergoing
ASCT in MCL.
Methods: Patients undergoing ASCT for MCL at the Ohio State
University in first remission with $ 3 chromosomal abnormalities
were considered complex. Cumulative incidence of relapse (CIR)
was measured from the date of transplant until the date of relapse,
censoring relapse-free patients at last follow-up. Death without re-
lapse (n 5 1) was treated as a competing risk event. Gray’s test was
used to evaluate differences in CIR.
Results: Of 37 patients, 78% were male. At diagnosis, median age
was 60 (range 37 to 74), 89% had bone marrow involvement, and
all were stage IV. ThemedianMIPIwas 5.9 (range 4.8 to 8.1). Induc-
tion regimens includedR-M-CHOP (n5 27), R-CHOP (n5 8), and
R-HyperCVAD (n5 2). Mobilization regimens included etoposide,
cytarabine, rituximab (EAR) (n 5 28), GCSF (n 5 2), GCSF with
plerixafor (n 5 4), cyclophosphamide (n 5 2), and etoposide (n 5
1). Conditioning regimens included BEAM (n 5 17), BEC (n 5
19), and busulfan, cyclophosphamide, and etoposide (n 5 1). Thir-
teen patients had complex cytogenetics (35%), including 4 with de-
letion of 17p. Complex patients were more likely to have an ECOG
PS$ 2 (p5 0.03), and higher median LDH at diagnosis (p5 0.01),
with no large differences in MIPI, age, sex, induction regimen, and
response to induction (p.0.20). Complex patients had a median
time to relapse of 14.8 months versus median not reached in the
non-complex group (HR 8.30, 95% CI 2.24 – 30.80, p 5 0.002). 3
of 4 complex patients with deletion 17p relapsed within 15 months
with 1 death at 5 months, but the time to relapse was still shorter
in remaining complex patients (p 5 0.01). The induction regimen
R-M-CHOP largely coincided with EAR and was associated with
longerCIR (p5 0.007) while response,MIPI, conditioning regimen,
age, sex, performance status, and LDH were not (p.0.20).
Conclusion: A complex karyotype predicts for a shorter time to re-
lapse in MCL patients undergoing ASCT in first remission. In addi-
tion, patients who received R-M-CHOP (all but 1 mobilized with
EAR) had prolonged time to relapse. Although complex patientsS205
S206 Oral Presentationswithout deletion 17p appear to also have shorter time to relapse,
more follow up is needed. Further investigation of risk stratification
of MCL patients according to cytogenetic subgroup is warranted.
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MAINTAINED HEMATOLOGIC AND ORGAN RESPONSES FOLLOWING RISK
ADAPTED STEM CELL TRANSPLANT (SCT) IN SYSTEMIC LIGHT-CHAIN
AMYLOIDOSIS (AL) USING BORTEZOMIB AND DEXAMETHASONE AS
CONSOLIDATION THERAPY
Landau, H.J.1, Hassoun, H.1, Rosenzweig, M.A.2, Bello, C.1, Hoover, E.1,
Riedel, E.1, Comenzo, R.L.3 1Memorial Sloan-Kettering Cancer Center,
New York, NY; 2City of Hope Cancer Center, Duarte, CA; 3TuftsMedical
Center, Boston, MA
Background:Risk-adaptedMELdosing has improved the safety but
may also compromise the efficacy of SCT for pts with AL.We report
results of a phase II trial using bortezomib and dexamethasone (BD)
as consolidation following risk-adapted SCT for pts with AL.
Methods:Newly diagnosed pts with AL involving # 2 organs were
assignedMEL 100, 140 or 200mg/m2 with SCT, based on age, renal
function and cardiac involvement. Response was assessed at 2-3, 12,
and 24 mos post-SCT. Pts with persistent clonal plasma cell disease
at 2-3 mos post-SCT received consolidation with BD for up to 6 cy-
cles. Organ response and overall survival (OS) were assessed at 12
and 24 mos post-SCT.
Results: 41 pts with kidney (71%), heart (46%), liver/GI (12%) and
peripheral nervous system (12%) disease were enrolled; 44% had 2
organ-involvement. One pt was ineligible; 1 is within 100 days of
SCT. Four pts with advanced cardiac AL died within 100 days of
SCT, resulting in 10% (4/40) TRM. With median follow-up 39
mos, OS at 12 mos post-SCT was 88%. In pts with heart involve-
ment OS was 74% and 58% at 12 and 24 mos respectively, versus
100% at both time points in those without cardiac AL (P 5 0003).
Increased BNP and troponin were associated with worse OS, HR
1.3 (P 5 0.0001) and HR 3.9 (P 5 0.0003), respectively. Post-
SCT, the hematologic RR was 54% with 28% pts achieving CR.
For persistent clonal disease, 65% (22/34) received BD. Among all
pts evaluable at 12 mos post-SCT, the hematologic RR was 96%
(26/27) with 67% CR; 1 pt progressed. At 24 mos post-SCT the
RR was 84% (16/19) including 50% who maintained CR; 3 more
pts progressed. Of pts who received BD, 89% had an improved he-
matologic response; all responded after 1 cycle. Organ responses
evolved over time and were seen in 56% and 88% of pts at 12 and
24 mos post-SCT, respectively. In pts with renal AL, 45% (9/20)
achieved an organ response at 12 mos which increased to 92% (12/
13) by 24 mos. No pt had worsening organ function.
Conclusions: In newly diagnosed AL pts, BD following risk-adapt-
ed SCT is effective for eradicating persistent clonal disease. Hema-
tologic responses are rapid resulting in high overall and
unprecedented CR rates. Organ function improves in the majority
of patients, over time. Cardiac disease is associated with inferior
OS and cardiac biomarkers are useful for assigning risk. Relapses oc-
cur after completion of therapy and a maintenance regimen follow-
ing post-SCT consolidation is worthy of further study.
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GEMCITABINE, BUSULFAN AND MELPHALAN (Gem/Bu/Mel) IS A NEW
HIGH-DOSE CHEMOTHERAPY (HDC) REGIMEN WITH HIGH ACTIVITY
IN REFRACTORY OR POOR-RISK RELAPSED NON-HODGKIN’S LYM-
PHOMA (NHL) PATIENTS RECEIVING AN AUTOLOGOUS STEM-CELL
TRANSPLANT (ASCT)
Nieto, Y.1, Jones, R.B.1, Popat, U.1, Andersson, B.1, Valdez, B.1,
Thall, P.2, Shpall, E.J.1, Chancoco, C.1, Alousi, A.1, Anderlini, P.1,
Hosing, C.1, Qazilbash, M.1, Bashir, Q.1, Kebriaei, P.1, Khoui, I.1,
Ciurea, S.1, Parmar, S.1, Rondon, G.1, Champlin, R.1 1UT MD Ander-
son Cancer Center, Houston, TX; 2UT MD Anderson Cancer Center,
Houston, TX
Background: BEAM is considered a standard HDC regimen for
ASCT for NHL. However, pts with primary refractory tumors (fail-
ure to achieve a CR to 1st-line treatment) or high-risk relapse have
poor outcomes after BEAM or similar regimens, underscoring the
need for more active HDC combinations.Methods:We developed a new HDC regimen combining gemcita-
bine (Gem) with busulfan (Bu) and melphalan (Mel) (Gem/Bu/Mel)
pursuing DNA damage repair inhibition. Gem was infused at a fixed
rate of 10 mg/m2/min (optimizing its intracellular activation) x 2
(days -8 and -3), immediately preceding the first doses of Bu and
Mel. Bu was given as 4 daily doses (d-8 to -5) targeting AUC
4,000/d. Mel was given at 60 mg/m2/d (d-3 and -2). Gem dose was
escalated by extending its infusion in sequential cohorts. Pts with
CD20+ tumors received rituximab at 375 mg/m2 (d+1 and +8).
This trial was open to pts with refractory lymphoid tumors. NHL
pts with primary refractory disease, CR1 \12 months or .1 re-
lapse/PD were eligible.
Results:GemMTDwas identified as an infusion length of 4.5 hours
(total dose 2,550 mg/m2/d), causing manageable mucositis and rash.
In this study we included 46 NHL pts: 30 B-LCL (16 primary
DLCL, 2 double-hit myc+/BCL2+ LCL, 4 transformed, 4 primary
mediastinal, 4 primary CNS), 3 Burkitt’s, 2 follicular, 11 T-NHL
(6 anaplastic, 2 PTCL, 2 NK/T, 1 angioimmunoblastic). Median
age 53 (26-66), median 3 (2-9) prior regimens (prior Gem in 6), prior
radiotherapy 10 pts. Primary refractory and poor-risk relapsed dis-
ease in 22 and 24 pts, respectively. Other prognostic features in-
cluded: 1) No. prior relapses: 1: N 5 17, .1: N 5 29; 2) IPI at
relapse/PD: 0-1: 7 pts, .1: 33 pts (.3: 8 pts), N/A: 6 pts; 3) high
LDH at relapse/PD: 13 pts; 4) PET negative at HDC: 23 pts,
PET positive: 23 pts (11 of these in PD at ASCT).
The CR and overall RR were: 1) B-LCL: 69% and 100%; T-
NHL: 66% and 66%; Burkitt’s and follicular: all pts had a CR. All
6 pts with prior gemcitabine (none of whom had responded to it)
had a CR toGem/Bu/Mel. At median follow-up of 16 (2-57)months,
the EFS and OS rates are: 1) B-LCL: 80% and 83%, respectively; 2)
T-NHL: both 73%; 3) Burkitt’s: all 3 pts relapsed at 3 months and
died; 4) Follicular: 1 pt alive in CR, 1 pt alive in relapse.
Conclusions: Our preliminary results in refractory or poor-risk re-
lapsed NHL suggest high activity of Gem/Bu/Mel, particularly in
the B-LCL and T-cell histologies. Disease-specific phase 2 trials
are warranted.
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COMPARISON OF GEMCITABINE, BUSULFAN ANDMELPHALAN (Gem/Bu/
Mel) WITH BEAM AND BUSULFAN/MELPHALAN (Bu/Mel) IN CONCUR-
RENT COHORTS OF REFRACTORY HODGKIN’S LYMPHOMA (HL)
PATIENTS RECEIVING AN AUTOLOGOUS STEM-CELL TRANSPLANT
Nieto, Y.1, Jones, R.B.1, Liu, P.2, Anderlini, P.1, Popat, U.1,
Andersson, B.1, Shpall, E.J.1, Alousi, A.1, Hosing, C.1, Kebriaei, P.1,
Qazilbash, M.1, Frazier, E.1, Chancoco, C.1, Bashir, Q.1, Ciurea, S.1,
Parmar, S.1, Champlin, R.1 1UTMDAnderson Cancer Center, Houston,
TX; 2UT MD Anderson Cancer Center, Houston, TX
Background: BEAM is considered a standard HDC regimen for pts
with Hodgkin’s lymphoma (HL) who are candidates for an ASCT.
However, pts with primary refractory tumors or high-risk relapse
have poor outcomes after BEAM, underscoring the need for more
active HDC combinations.
Methods:We have developed a new HDC regimen of gemcitabine
(Gem), busulfan (Bu) and melphalan (Mel) (Gem/Bu/Mel), exploit-
ing their synergy based on DNA damage repair inhibition. At its
MTD, Gem was infused at a fixed dose rate of 10 mg/m2/min (opti-
mizing its intracellular activation) over 4.5 hours (d-8 and -3) (total
dose 5,550 mg/m2), preceding the first doses of Bu or Mel. Bu was
given as 4 daily doses (d-8 to -5) targeting AUC 4,000/d x4. Mel
was given at 60 mg/m2/d x2 (d-3 and -2). We compared the subset
of refractory HL pts of this study with all other refractory HL pts
transplanted during the same period at our institution, who were el-
igible for this trial but either received BEAMoff protocol or were en-
rolled in a separate trial of Bu/Mel. All of them met $1 of the
following criteria: primary induction failure (PIF) (\CR to 1st line
chemotherapy), CR1\6 mo, or .1 relapse. Pts with relapsed and
non-refractory HL were excluded from this analysis.
Results:We analyzed 209 pts in these cohorts: 1) Gem/Bu/Mel (N
5 89) (Jan 07-June 11), median f/u: 16 (3-57)mo; 2) BEAM (N5 83)
(Jan 05-Aug 11), median f/u: 17 (2-56) mo; 3) Bu/Mel (N5 37) (Apr
05-Dec 07), median f/u: 36 (17-56) mo. The Gem/Bu/Mel cohort
had substantially higher % PIF, .1 relapses, bulky tumors (.5
cm) at relapse/PD, extranodal disease at relapse/PD, PET+ tumors
at HDC and PD at HDC.
